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Abstract
Background:  Streptococcus (S.) pneumoniae meningitis has a high lethality despite antibiotic
treatment. Inflammation is a major pathogenetic factor, which is unresponsive to antibiotics.
Therefore adjunctive therapies with antiinflammatory compounds have been developed. TNF484
is a TNF-alpha converting enzyme (TACE) inhibitor and has been found efficacious in experimental
meningitis. Toll-like receptor 2 (TLR2) contributes to host response in pneumococcal meningitis
by enhancing bacterial clearing and downmodulating inflammation. In this study, TNF484 was
applied in mice, which lacked TLR2 and exhibited a strong meningeal inflammation.
Methods: 103 CFU S. pneumoniae serotype 3 was inoculated subarachnoidally into C57BL/6 wild
type (wt) mice or TLR2-/-, CD14-/- and CD14-/-/TLR2-/- mice. Severity of disease and survival was
followed over 9 days. Response to antibiotics (80 mg/kg ceftriaxone i.p. for 5 days) and/or TACE
inhibitor treatment (1 mg/kg s.c. twice daily for 4 days) was evaluated. Animals were sacrificed after
12, 24, and 48 h for analysis of bacterial load in cerebrospinal fluid (CSF) and brain and for TNF and
leukocyte measurements in CSF.
Results: TLR2-/- mice were significantly sicker than the other mouse strains 24 h after infection.
All knockout mice showed higher disease severity after 48 h and died earlier than wt mice. TNF
release into CSF was significantly more elevated in TLR2-/- than in the other strains after 24 h. Brain
bacterial numbers were significantly higher in all knockout than wt mice after 24 h. Modulation of
outcome by antibiotic and TACE inhibitor treatment was evaluated. With antibiotic therapy all wt,
CD14-/- and TLR2-/-/CD14-/- mice, but only 79% of TLR2-/- mice, were rescued. TACE inhibitor
treatment alone did not rescue, but prolonged survival in wt mice, and in TLR2-/- and CD14-/- mice
to the values observed in untreated wt mice. By combined antibiotic and TACE inhibitor treatment
95% of TLR2-/- mice were rescued.
Conclusion:  During pneumococcal meningitis strong inflammation in TLR2-deficiency was
associated with incomplete responsiveness to antibiotics and complete response to combined
antibiotic and TACE inhibitor treatment. TACE inhibitor treatment offers a promising adjuvant
therapeutic strategy in pneumococcal meningitis.
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Background
Streptococcus pneumoniae is the cause of the most severe
and most frequent form of adult bacterial meningitis [1].
Therapy with antibiotics is only partially effective in pre-
venting mortality and development of neurologic seque-
lae [2]. Inflammation contributes to morbidity and
mortality, but is itself unresponsive to antibiotics [3]. New
adjunctive therapies reducing inflammatory molecules
are needed [4]. In this respect, TNF and matrix-metallo-
proteases (MMPs) are major therapeutic targets since both
molecules are up-regulated early [5]; TNF levels in CSF are
related to disease severity [6] and TNF and MMP's contrib-
ute to brain injury during pneumococcal meningitis [7-9].
TNF and its receptors are shed from the membrane by TNF
alpha converting enzyme (TACE) [7]. TNF484 is a novel
water-soluble inhibitor of MMPs and TACE release, which
is active in vitro [10] and has been found efficacious in
experimental rat meningitis [9]. The pattern recognition
receptor TLR2 is expressed on resting mouse phagocytes
[11] and mediates inflammatory responses to cell wall
lipoteichoic acid and membrane lipoproteins of Gram-
positive bacteria [12,13]. Live Gram-positive bacteria,
while expressing TLR2 ligands on their surface, do not
depend on TLR2 for phagocytosis and killing, nor for
induction of inflammation; however, TLR2 modulates
infection. We and others found accelerated mortality of
TLR2-/-mice with pneumococcal meningitis [6,14]. Early
death was associated with high brain bacterial load, and
strong TNF expression in brain infiltrating cells. Excess
TNF in TLR2-/- mice was not due to higher infiltrating leu-
kocyte numbers in this strain, but to excess expression of
TNF per cell [11,15]. Our resullts indicate that TLR2 func-
tions both to upregulate inflammation in response to bac-
terial components and to downregulate inflammation
elicited by infection with live S. pneumoniae. Besides TLR2,
CD14 was also recognized as receptor for Gram-positive
cell wall components [16,17]. It is poorly expressed in
resting mouse phagocytes [18] and strongly induced upon
stimulation with bacterial components or infection in
vitro  and  in vivo [18,19]. This suggests a role in host
immune response [20]. The association of CD14 with
TLR2 in a heteromeric complex was shown to be required
for cell activation by TLR2 ligands [13,21-23], and
recently lipopeptide binding to CD14 was found to
induce proximity between CD14, TLR2 and TLR1 [21]. In
pneumococcal meningitis, we found a shorter survival in
CD14-/- than in wt mice, which was due to enhanced
CXCR2 expression leading to early recruitment of leuko-
cyte and increased TNF in cerebrospinal fluid (CSF) [18].
From our in vivo studies using single knockout mice, it
appears that TLR2 and CD14 both are protective in men-
ingitis, although by different mechanisms. Because both
strains showed excessive TNF, we compared the treatment
response in wt, TLR2-/-, CD14-/-, and CD14-/-/TLR2-/-dou-
ble knockout mice with meningitis to antibiotic treatment
and/or anti-inflammatory treatment with TACE inhibitor.
Methods
Preparation of bacterial inocula
Streptococcus pneumoniae (clinical isolate of serotype 3,
H14) were grown for 7 h in double Mueller Hinton broth
(MHB) (DIFCO Laboratories Detroit, USA), then subcul-
tured overnight in new MHB, and washed in 0.9% sterile
saline (12,000 × g for 6 min) immediately before use. The
inoculum size was calculated from optical density (OD)
determinations (OD 0.4 = 1 × 108 CFU/ml) and was retro-
spectively assessed by CFU counting on blood agar plates.
Mouse meningitis model
Six to eight week old C57BL/6 (wild type, wt) were bred at
the Animal House of the University Hospital Basel. TLR2-
/- mice were kindly provided by William J. Rieflin (Tularik,
South San Francisco, CA) and CD14-/- mice by Mason
Freeman (Massachusetts General Hospital, Boston). Both
mouse strains had been backcrossed for 10 generations on
a C57BL/6 background. The two strains with targeted gene
deletions were crossed to obtain TLR2-/-/CD14-/-double
knockout mice. All animals were kept under specific path-
ogen free conditions in the Animal House of the Depart-
ment of Research, University Hospital Basel according to
the regulations of the Swiss veterinary law. Mice were
anaesthetized via intraperitoneal (i.p.) injection of 100
mg/kg Ketamine (Ketalar©; Warner-Lambert AG, Baar,
Switzerland) and 20 mg/kg Xylazinum (Xylapan©; Graeub
AG, Bern, Switzerland), and subsequently subarachnoi-
dally inoculated into the left forebrain with either 0.9%
NaCl or live S. pneumoniae (2 × 102 or 3 × 103 CFU) in a
25 μl volume. The health status of the mice was assessed
by the following scores as described previously [7]: (1)
normal motor activity and turned upright in <5 s when
put on their back; (2) decreased spontaneous activity, but
still turned up in <5 s; (3) turned up in >5 s; (4) did not
turn up; (5) did not move. After 6, 12, 24, 48 and 72 h or
if they presented score 5, mice were sacrificed by i.p. injec-
tion of 100 mg/kg pentobarbital (Abbott Laboratories,
North Chicago, IL). Animals were perfused with Ringer's
solution (Braun Medical AG, Emmenbrücke, Switzerland)
into the left cardiac ventricle. Cerebrospinal fluid (CSF)
was harvested by puncture of the cisterna magna as
described previously [20]. Due to the small volumes (3–6
μl) obtained from each animal, CSF from 3 mice were
pooled.
Determination of bacterial counts and inflammatory 
parameters
Leukocytes in CSF were counted in a hematocytometer
and differentiated by Wright stain on cytospin prepara-
tions. Then CSF was serially diluted in 0.9% saline to
assess the bacterial load after plating and incubation atBMC Infectious Diseases 2007, 7:25 http://www.biomedcentral.com/1471-2334/7/25
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37°C for 24 h. Cell free CSF was obtained by centrifuga-
tion at 800 × g for 7 min (room temperature) and samples
were stored at -20°C until cytokine determination. For
histology, brains were fixed in 4% paraformaldehyde, par-
affin embedded and stained with haematoxylin-eosin
(H&E). For bacterial counting, brains were homogenized
with a Polytron homogenizer in 1 ml of phosphate buffer
saline (PBS). Bacterial titers were determined by plating
serial 10-fold dilutions in 0.9% saline on blood agar
plates. The concentration of the pro-inflammatory
cytokine TNF in CSF was determined with a bioassay,
measuring the degree of cytotoxicity on WEHI cells in the
presence of 1 μg/ml actinomycin D, and with use of
mouse rTNF as a standard. Matrix metalloproteinase 9
was determined with zymography from gelatine-sepha-
rose purified, frozen brain homogenates as described pre-
viously [8].
Treatment
Treatments with antibiotic and TACE inhibitor were per-
formed as previously described [6,7]. Briefly, mice were
treated with either 80 mg/kg ceftriaxone (Rocephin, Hoff-
mann-La Roche, Switzerland, dissolved in 0.1 ml saline)
via i.p. injection twice daily for 5 days and/or with subcu-
taneous (s.c.) injection of 1 mg/kg water soluble TACE
inhibitor TNF484 twice daily for 4 days. Treatments with
TNF484 and antibiotics were started 12 h and 18 h after
infection, respectively.
Statistical analysis
Differences in survival between different mouse strains
and treatments were analyzed using the log rank test and
Kaplan-Meier analysis. CFU, leukocytes and TNF in the
four mouse strains at different time points were compared
with repeated-measures analysis of variance (ANOVA).
Results
Survival of TLR2-/-, CD14-/- and TLR2-/-/CD14-/-mice after 
antibiotic therapy
TLR2-/-, CD14-/-and C57BL/6 (wt) mice used in this study
were described in previous published papers [6,18]. The
early course of meningitis differed in the three knockout
strains. After 24 h, a large fraction of TLR2-/- mice (41%)
showed severe clinical symptoms, whereas in wt, CD14-/-
and TLR2-/-/CD14-/- mice, only a small proportion of mice
(less than 16%) was severely sick (Fig. 1A). After 48 h, all
knockout strains showed significantly more animals with
high severity scores than wt mice (Fig. 1A). Accordingly,
survival was significantly shortened in all knockout com-
pared to wt mice (p < 0.02 in log-rank test; Fig. 1B). Anti-
biotic treatment is efficient in mouse [24] and human
meningitis [25], if treatment starts early. Accordingly mice
were treated with ceftriaxone for 5 days starting 18 h after
infection. While wt, CD14-/-  and TLR2-/-/CD14-/-  mice
were rescued (Fig. 1C), antibiotics were insufficient in
TLR2-/- mice and 21.2% of TLR2-/- mice died (p < 0.05,
compared to the other mouse strains). Most likely, antibi-
otics are less efficient under conditions of established, del-
eterious inflammation, which follows accumulation of
bacteria. In our study the bacterial load and consequently
the extent of inflammation may have influenced the anti-
biotic response. Therefore these parameters were com-
pared in the different mouse strains. Bacterial load and
TNF in TLR2-/-, CD14-/-  and TLR2-/-/CD14-/-  mice was
assessed simultaneously in all knockout mice after infec-
tion and values in knockout strains were compared to
those in wt mice. Bacterial numbers in CSF were similar in
all strains 24 h after infection (data not shown), indicat-
ing that planctonic bacteria recovered in CSF did not rep-
resent an early pathogenetic factor, which contributed to
the more severe clinical picture of the TLR2-/- strain. In
contrast CFU numbers collected in brain homogenates
were higher in all knockout than in wt mice 24 h after
infection (p < 0.05, Fig. 2A). After 48 h, values in TLR2-/-/
CD14-/- mice remained higher than in the other strains (p
< 0.01, Fig. 2A). TNF levels in CSF were barely detectable
after 12 h, but after 24 h TLR2 deficiency was accompa-
nied by a stronger inflammation, recorded as higher TNF
level in CSF (Fig. 2B) as compared to CD14-/- and to wt
mice. Mice deficient in both TLR2 and CD14 showed
hardly any elevation of TNF with values remaining below
100 pg/ml. After 48 h all knockout mice showed low level
of TNF (below 100 pg/ml) in CSF. Since in meningitis,
TNF in CSF is mainly derived from infiltrating cells, the
extent of leukocyte infiltration might have determined
TNF levels in the four strains. However, compared to wt
mice, TLR2-/- mice presented even a reduced influx (Fig.
2C), CD14-/- mice had an increased influx and TLR2-/-/
CD14-/- mice had similar leukocyte numbers as wt mice at
12 h after infection. Twenty-four and 48 h after infection,
the values were similar in all mouse strains (Fig. 2C).
These results indicate, that the control of TNF and leuko-
cyte migration by TLR2 and CD14 were not linked, and
high TNF was produced in TLR2-/- mice despite low leuko-
cyte numbers.
Our results show an effect on bacterial clearing of both
TLR2 and CD14, a TNF-downregulating effect of TLR2 and
an opposite effect of TLR2 and CD14 respectively on early
leukocyte migration.
Effect of TACE inhibitor on meningitis in TLR2-/- and CD14-
/- mice
TLR2-/-mice could not be rescued with antibiotics and
showed excess TNF in CSF. Therefore, the treatment of
choice in TLR2-/- mice was an anti-inflammatory adjunc-
tive drug. Based on our earlier studies with TNF484 in
neonatal rat pneumococcal meningitis [26], we con-
firmed in our mouse meningitis model, that TNF484
treatment starting 12 h after infection reduced CSF infil-BMC Infectious Diseases 2007, 7:25 http://www.biomedcentral.com/1471-2334/7/25
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A) Percentage of wt (n = 40), TLR2-/- (n = 35), CD14-/- (n = 29) and TLR2-/-/CD14-/- (n = 31) mice showing high severity score  (including score higher than 2.5) after infection with S. pneumoniae Figure 1
A) Percentage of wt (n = 40), TLR2-/-(n = 35), CD14-/- (n = 29) and TLR2-/-/CD14-/- (n = 31) mice showing high severity score 
(including score higher than 2.5) after infection with S. pneumoniae. Mean ± SD of four independent experiments (p < 0.02, 
ANOVA). B) Mortality from untreated pneumococcal meningitis: wt (n = 33), TLR2-/- (n = 24), CD14-/- (n = 21) and TLR2-/-/
CD14-/- (n = 10) mice. C) Effect of antibiotic treatment in wt (n = 15), TLR2-/- (n = 15), CD14-/- (n = 9) and TLR2-/-/CD14-/- (n 
= 9) mice. Arrow indicates start of ceftriaxone therapy.
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A) Bacterial numbers in brain 12, 24 and 48 h after infection with 3 × 103 CFU of S. pneumoniae in wt (n = 18), TLR2-/- (n = 18),  CD14-/- (n = 17) and TLR2-/-/CD14-/- (n = 6) mice Figure 2
A) Bacterial numbers in brain 12, 24 and 48 h after infection with 3 × 103 CFU of S. pneumoniae in wt (n = 18), TLR2-/- (n = 18), 
CD14-/- (n = 17) and TLR2-/-/CD14-/- (n = 6) mice. Median values and 25–75% spread (p < 0.02, ANOVA). B) TNF levels in CSF 
in wt (n = 21), TLR2-/- (n = 13), CD14-/- (n = 14) and TLR2-/-/CD14-/- (n = 6) mice 12 and 24 h after infection. Mean values ± SD 
(p < 0.02, ANOVA). C) Leukocyte numbers in CSF in wt (n = 15), TLR2-/- (n = 10), CD14-/- (n = 14) and TLR2-/-/CD14-/- (n = 
6) mice 12 to 48 h after infection. Median values (p < 0.02, ANOVA).
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trating leukocytes in infected mice by 50% from 6.38 ×
104 ± 5.88 × 104 to 3.22 × 104 ± 1.82 × 104 leukocytes/μl
CSF, respectively. Histology confirmed the reduction of
leukocyte infiltration; in TACE-treated brain no leuko-
cytes could be detected (Fig. 3C, left), whereas in
untreated infected brains massive leukocyte infiltration
was detected (Fig. 3C, right), MMP-9 in brain homoge-
nates of infected and TNF484 – treated mice was reduced
to 10% of the value found in infected mice, respectively
and TNF in CSF to non-measurable values (data not
shown). TNF484 treatment did not rescue mice to 100%
survival, but mortality was significantly delayed in both
knockout and wt mice (p < 0.05). In TLR2-/-(Fig. 3A) and
CD14-/-  (Fig. 3B) animals, this treatment significantly
slowed death to the rate observed in untreated wt mice.
Survival of wt mice was also significantly prolonged by
TNF484 treatment (p < 0.05), which indicates a better out-
come in mice receiving anti-inflammatory therapy.
Effect of antibiotics and TNF484 combined in TLR2-/- mice
Wt, CD14-/-and TLR2-/-/CD14-/-mice, but not TLR2-/-mice
were rescued by antibiotics. According to the individual
effects of ceftriaxone and TNF484 in TLR2-/-mice (Fig. 1C
and 3A), combining both treatments was expected to
result in an additive effect. Therefore, efficacy of the com-
bined TNF484 and antibiotic therapy on outcome of
TLR2-/- mice was assessed. Two groups of TLR2-/-mice
treated either with ceftriaxone alone or with ceftriaxone
combined with TNF484 were compared. TLR2-/-mice
receiving combined treatment all survived, this was a sig-
nificantly better outcome compared to TLR2-/-mice, which
received ceftriaxone alone (p < 0.05) (Fig. 4). DKO mice
were not treated with TACE inhibitor since they developed
a weak meningeal inflammation no effect on TNF could
be expected.
Discussion
This study has compared outcome and treatment effects of
antibiotics and TACE inhibitor TNF484 during pneumo-
coccal meningitis in mice lacking the pattern recognition
receptors TLR2 and/or CD14. We found that wt mice with
untreated  S. pneumoniae meningitis lived longer than
infected mice with a genetic deletion of TLR2 or CD14 or
both TLR2 and CD14. The time to death was similar in all
untreated KO strains. However, antibiotics rescued all wt,
CD14-/-and TLR2-/-/CD14-/- mice and only 79% of the
TLR2-/- mice. This indicates that different mechanisms led
to earlier death in the 3 KO mouse strains. TLR2-/- mice
presented earlier a more severe disease with higher TNF in
CSF than the other strains, thus in these animals death
despite antibiotic therapy was most likely due to increased
inflammation. Accordingly, the treatment of choice in
TLR2-/- mice was an anti-inflammatory adjunctive drug.
Based on our earlier studies with TACE inhibitor TNF484
in neonatal rat pneumococcal meningitis [26], we first
confirmed that TNF484 used at 1 mg/kg twice daily
blocked TNF and MMP-9 in CSF of infected mice. TACE
inhibitor treatment was able to reduce inflammation in
all mouse strains studied. Wt mice, which had a longer
survival if untreated, were similarly improved as TLR2-
and CD14-deficient animals, which had a shorter survival
if untreated. Since infected TLR2-/-mice were not rescued
by administration of either antibiotics or TACE inhibitor
alone, combined treatment was applied and resulted in
95% survival in this mouse strain. It can be hypothesized
that TNF484 treatment reduced the inflammation which
was induced by the cell wall components released during
ceftriaxone therapy [27]. In an earlier study, penicillin
treatment of S. pneumoniae led to release of inflammatory
products [28]. Since antibiotic-induced S. pneumoniae
fragments activated host cells via TLR2 [29], it is unlikely
that in TLR2-/- mice TNF484 treatment reduced the inflam-
mation, which was induced by the cell wall components
released during ceftriaxone therapy [27].
To elucidate the reasons for the differential treatment
response in the 4 mouse strains, bacterial load, CSF leuko-
cyte numbers and TNF, which are the major determinants
of outcome, were studied. CFU in CSF are derived from
planctonic bacteria, they were not different early in dis-
ease among the different mouse strains. Since we observed
that pneumococci are strongly adherent to plexus epithe-
lia [30], bacterial load in brain homogenates was evalu-
ated. 24 h after infection brain bacterial load was similarly
increased in all the KO strains compared to C57BL/6
mice. We have previously investigated the effector mecha-
nism of TLR2 upon bacterial clearance. Early increased
brain bacterial load in TLR2-/- mice [6] was associated with
a stronger pneumococcal adherence to plexus choroideus
epithelial cells in TLR2-deficient brains [30]. In addition,
we found phagocytosis of pneumococci delayed and oxi-
dative killing reduced in TLR2-/- compared to wt granulo-
cytes in vitro (14). These results are in agreement with
impaired phagosome maturation, as described in TLR2-
deficient macrophages after ingestion of killed bacteria
[31,32]. Thus TLR2 appears to improve bacterial clearance
by reducing adherence and accelerating pathogen uptake.
In contrast, we found no early direct effect of CD14 upon
bacterial numbers in vivo [18] and no effect upon pneu-
mococcal phagocytosis of CD14 in vitro (unpublished
results). Nevertheless after 48 h of infection TLR2-/-/CD14-
/-mice had higher concentrations of bacteria in both CSF
and brain than either TLR2-/-or CD14-/-mice. This indi-
cates that TLR2 has a primary effect upon bacterial clear-
ance, which is supported by CD14.
We previously described a delayed early leukocyte recruit-
ment to CSF in TLR2-/- mice [6] and an accelerated leuko-
cyte immigration in CD14-/- compared to wt mice [18]
(Fig. 2C). These findings imply that the early high TNFBMC Infectious Diseases 2007, 7:25 http://www.biomedcentral.com/1471-2334/7/25
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Effect of TACE inhibitor (TNF484) treatment in wt, TLR2-/-and CD14-/-mice on outcome of pneumococcal meningitis Figure 3
Effect of TACE inhibitor (TNF484) treatment in wt, TLR2-/-and CD14-/-mice on outcome of pneumococcal meningitis. A) Sur-
vival rate in wt untreated (n = 25, NaCl) and treated (n = 37, TNF484), p < 0.05; TLR2-/- untreated (n = 25, NaCl) and treated 
(n = 25, TNF484), p < 0.05; wt untreated and TLR2-/- treated: p > 0.05. B) Survival rate in wt untreated (n = 25, NaCl) and 
treated (n = 37, TNF484), p < 0.05; CD14-/- untreated (n = 21, NaCl) and treated (n = 12, TNF484), p < 0.05. Dashed arrow 
indicates start of TNF484 therapy. C) HE-stained sections of brains from wt mice 24 h after infection with (left panel) or with-
out (right panel) TNF484 treatment. One representative example is shown for each group.
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levels in TLR2-/- mice were not related to high leukocyte
numbers in CSF. Instead, we found a NF-κB-dependent
excess of pro-over anti-inflammatory cytokine mRNA
with an increased TNF and a decreased IL-10 transcription
and increased TNF protein in brain leukocytes at the ori-
gin of early increased TNF in TLR2-/- mice [15]. In contrast,
in CD14-/-mice no such changes were observed according
to our previous study [18]. Interestingly TLR2/CD14 KO
mice produced less TNF than wt mice, which indicates
that besides TLR2 as the major regulator, CD14 partici-
pates in a temporally and locally coordinated action in
controlling TNF during pneumococcal infection.
Conclusion
Our treatment study compares the host response medi-
ated by TLR2 and CD14 in meningitis, and illustrates the
requirement and success of adjuvant therapy, under con-
ditions of harmful inflammation in TLR2-deficient mice.
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